CTLA4 and neoplasm: One of the key therapies involves the use of immune checkpoint inhibitors (ICIs), which enhance the anti-tumor activity of immune cells by blocking specific immune checkpoints, such as programmed death receptor 1/programmed death-ligand 1(PD-1/PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), among others.